Neurology Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Stroke, Multiple Sclerosis, Migraine, Others), By End-User (Pharmaceutical & Biotech Companies, Hospitals & Clinics, Contract Research Organizations (CROs), Academic & Research Institutes, Government & Non-profit Organizations, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025–2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Neurology Clinical Trials Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. How does increasing neurodegenerative disease prevalence accelerate demand for innovative neurology trials?

3.2.2. Why is rising pharmaceutical R&D investment driving expansion within neurology-focused clinical studies?

3.2.3. In what ways does advance digital technology adoption improve the efficiency of neurological research?

3.3. Key industry pitfalls & challenges

3.3.1. How do high operational costs create barriers for conducting global neurology trials?

3.3.2. Why does patient recruitment complexity hinder the progression of clinical research in neurological conditions?

3.3.3. What regulatory challenges slow approval processes impacting the commercialization of neurological treatment candidates?

3.4. Market Opportunities

3.4.1. How can decentralized trial models enhance accessibility for participants across diverse geographies?

3.4.2. Why will personalized medicine innovations unlock breakthroughs in neurology disorder-targeted therapies?

3.4.3. In what ways does strategic collaboration improve global neurology research ecosystem growth?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Neurology Clinical Trials Market, Phase Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Phase, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Phase I

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Phase II

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Phase III

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Phase IV

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Neurology Clinical Trials Market, Study Design Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Study Design, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Interventional

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Observational

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Expanded Access

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Neurology Clinical Trials Market, Indication Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Indication, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Amplifiers Alzheimer’s Disease

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Parkinson’s Disease

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Epilepsy

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Stroke

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Multiple Sclerosis

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Migraine

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.8. Others

6.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Neurology Clinical Trials Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Pharmaceutical & Biotech Companies

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Hospitals & Clinics

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Contract Research Organizations (CROs)

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Academic & Research Institutes

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Government & Non-profit Organizations

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.7. Others

7.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Neurology Clinical Trials Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Phase, 2025-2035

8.2.3. North America Market Revenue, By Study Design, 2025-2035

8.2.4. North America Market Revenue, By Indication, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Phase, 2025-2035

8.2.6.2. U.S. Market Revenue, By Study Design, 2025-2035

8.2.6.3. U.S. Market Revenue, By Indication, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Phase, 2025-2035

8.2.7.2. Canada Market Revenue, By Study Design, 2025-2035

8.2.7.3. Canada Market Revenue, By Indication, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Phase, 2025-2035

8.3.3. Europe Market Revenue, By Study Design, 2025-2035

8.3.4. Europe Market Revenue, By Indication, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Phase, 2025-2035

8.3.6.2. Germany Market Revenue, By Study Design, 2025-2035

8.3.6.3. Germany Market Revenue, By Indication, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Phase, 2025-2035

8.3.7.2. France Market Revenue, By Study Design, 2025-2035

8.3.7.3. France Market Revenue, By Indication, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Phase, 2025-2035

8.3.8.2. U.K. Market Revenue, By Study Design, 2025-2035

8.3.8.3. U.K. Market Revenue, By Indication, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Phase, 2025-2035

8.3.9.2. Italy Market Revenue, By Study Design, 2025-2035

8.3.9.3. Italy Market Revenue, By Indication, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Phase, 2025-2035

8.3.10.2. Spain Market Revenue, By Study Design, 2025-2035

8.3.10.3. Spain Market Revenue, By Indication, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Phase, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Study Design, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Indication, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Phase, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Study Design, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Indication, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Phase, 2025-2035

8.4.6.2. China Market Revenue, By Study Design, 2025-2035

8.4.6.3. China Market Revenue, By Indication, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Phase, 2025-2035

8.4.7.2. Japan Market Revenue, By Study Design, 2025-2035

8.4.7.3. Japan Market Revenue, By Indication, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Phase, 2025-2035

8.4.8.2. India Market Revenue, By Study Design, 2025-2035

8.4.8.3. India Market Revenue, By Indication, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Phase, 2025-2035

8.4.9.2. Australia Market Revenue, By Study Design, 2025-2035

8.4.9.3. Australia Market Revenue, By Indication, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Phase, 2025-2035

8.4.10.2. South Korea Market Revenue, By Study Design, 2025-2035

8.4.10.3. South Korea Market Revenue, By Indication, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Phase, 2025-2035

8.4.11.2. Singapore Market Revenue, By Study Design, 2025-2035

8.4.11.3. Singapore Market Revenue, By Indication, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Phase, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Study Design, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Phase, 2025-2035

8.5.3. Latin America Market Revenue, By Study Design, 2025-2035

8.5.4. Latin America Market Revenue, By Indication, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Phase, 2025-2035

8.5.6.2. Brazil Market Revenue, By Study Design, 2025-2035

8.5.6.3. Brazil Market Revenue, By Indication, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Phase, 2025-2035

8.5.7.2. Argentina Market Revenue, By Study Design, 2025-2035

8.5.7.3. Argentina Market Revenue, By Indication, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Phase, 2025-2035

8.5.8.2. Mexico Market Revenue, By Study Design, 2025-2035

8.5.8.3. Mexico Market Revenue, By Indication, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Phase, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Study Design, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Indication, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Phase, 2025-2035

8.6.3. MEA Market Revenue, By Study Design, 2025-2035

8.6.4. MEA Market Revenue, By Indication, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Phase, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Study Design, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Indication, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Phase, 2025-2035

8.6.7.2. South Africa Market Revenue, By Study Design, 2025-2035

8.6.7.3. South Africa Market Revenue, By Indication, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Phase, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Study Design, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Indication, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. Novartis International AG

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Biogen Inc.

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. F. Hoffmann-La Roche Ltd.

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Eli Lilly and Company

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. AbbVie Inc.

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Sanofi S.A.

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Merck & Co., Inc.

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. GlaxoSmithKline plc (GSK)

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. AstraZeneca plc

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Eisai Co., Ltd.

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Teva Pharmaceutical Industries Ltd.

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Pfizer Inc.

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Bayer AG

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Johnson & Johnson Services, Inc.

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Takeda Pharmaceutical Company Limited.

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis